These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 619863)

  • 21. Causes of the epidemic of coronary heart disease.
    Stamler J
    Brux Med; 1973 Sep; 53(9):473-502. PubMed ID: 4756144
    [No Abstract]   [Full Text] [Related]  

  • 22. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
    Hunninghake DB
    Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management.
    Assmann G
    Am J Cardiol; 2001 Mar; 87(5A):2B-7B. PubMed ID: 11256848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Focus on hyperlipidaemia. Rational and practical guidelines for reducing the risk of coronary heart disease.
    DiBianco R
    S Afr Med J; 1992 Feb; Suppl():1-9. PubMed ID: 1542809
    [No Abstract]   [Full Text] [Related]  

  • 25. Management of blood lipid abnormalities in coronary heart disease patients.
    Kuo PT
    Clin Cardiol; 1989 Oct; 12(10):553-60. PubMed ID: 2680196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipids in women: screening and treatment.
    Walsh JM
    J Am Med Womens Assoc (1972); 2003; 58(4):240-7. PubMed ID: 14640255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid management in diabetic patients: lessons from prevention trials.
    Gotto AM
    Am J Med; 2002 Jun; 112 Suppl 8A():19S-26S. PubMed ID: 12049991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triglycerides and coronary heart disease: a global perspective.
    Ahmad I; Miller M
    J Cardiovasc Risk; 2000 Oct; 7(5):303-7. PubMed ID: 11143759
    [No Abstract]   [Full Text] [Related]  

  • 30. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments for].
    de Teresa Galván E; Jiménez Navarro M
    Rev Esp Cardiol; 1996 Jul; 49(7):483-5. PubMed ID: 8754441
    [No Abstract]   [Full Text] [Related]  

  • 31. Lipid regulation: a clinician's view of patient management.
    Scheidt S
    Am Heart J; 1986 Aug; 112(2):437-40. PubMed ID: 3526856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Epidemiology of coronary heart disease : past, present and future (author's transl)].
    Kornitzer M
    Rev Med Brux; 1980 Apr; 1(4):247-58. PubMed ID: 7466023
    [No Abstract]   [Full Text] [Related]  

  • 33. Dietary fats and coronary heart disease: unfinished business.
    Ahrens EH
    Lancet; 1979 Dec 22-29; 2(8156-8157):1345-8. PubMed ID: 92686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperlipidemia and coronary atherosclerosis: a review.
    Inkeles S; Eisenberg D
    Medicine (Baltimore); 1981 Mar; 60(2):110-23. PubMed ID: 7012540
    [No Abstract]   [Full Text] [Related]  

  • 35. [KLAS [Kanazawa Lipid Assessment Survey]].
    Mabuchi H; Inazu A; Higashikata T; Nohara A; Koizumi J
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():469-76. PubMed ID: 11347115
    [No Abstract]   [Full Text] [Related]  

  • 36. Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database).
    Albert NM; Birtcher KK; Cannon CP; Goff DC; Mulgund J; Liang L; Fonarow GC
    Am J Cardiol; 2008 May; 101(9):1242-6. PubMed ID: 18435951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highlights of current research in atherosclerosis.
    Schettler G
    Adv Exp Med Biol; 1977; 82():9-14. PubMed ID: 920446
    [No Abstract]   [Full Text] [Related]  

  • 38. The laboratory's role in identifying lipid and lipoprotein risk factors for CHD.
    McNamara JR; Seman LJ; Schaefer EJ
    MLO Med Lab Obs; 1999 Oct; 31(10):24-8, 30-6, 51; quiz 38-9. PubMed ID: 11184276
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of almond dietary supplementation on coronary heart disease lipid risk factors and serum lipid oxidation parameters in men with mild hyperlipidemia.
    Jalali-Khanabadi BA; Mozaffari-Khosravi H; Parsaeyan N
    J Altern Complement Med; 2010 Dec; 16(12):1279-83. PubMed ID: 21114415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments against].
    Brotons Cuixart C; Maiques Galán A
    Rev Esp Cardiol; 1996 Jul; 49(7):486-91. PubMed ID: 8754442
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.